Paper alert
Paper alert
复制标题
DOI：
10.1097/01.meg.0000263815.03674.6a
复制
发表时间：
2007-07
影响因子：
2.1
通讯作者：
J. Plevris
中科院分区：
文献类型：
--
作者：
J. Plevris
那他珠单抗治疗活动性克罗恩病：ENCORE试验的结果Targan SR，Feagan BG，Fedorak RN，Lashner BA，Panaccione R，Present DH，Spehlmann ME，Rutgeolan PJ，Tulassay Z，Volfova M，Wolf DC，埃尔南德斯C，Bornstein J，Sandborn WJ;那他珠单抗在克罗恩病应答和缓解中的国际疗效（ENCORE）试验组背景和目的：一项随机安慰剂对照试验评估了那他珠单抗诱导治疗克罗恩病患者的疗效。
Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group Background and aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn’s disease.